A photo of Nadim Khalil.

Nadim Khalil, MD

  • Clinical Fellow, Division of Infectious Diseases



My primary research area is studying predisposing components and results linked with resistant gram-negative invasive infections. I’m investigating the risks that lead patients to have a higher chance of becoming infected due to a resistant pathogen.

I am very interested in pinpointing the risk factors that pose a greater likelihood of patients acquiring an infection from a resistant pathogen. Figuring out this information would be quite useful for providers treating patients at risk of aggressive infections by lowering the incidence of resistant pathogens.

I recognized my passion for infectious disease research during my medical school training. I worked with many patients with multi-drug resistant bacteria, including Vancomycin-resistant enterococci, multi-drug-resistant tuberculosis and Carbapenem-resistant Enterobacteriaceae. The exposure to these patients elevated my awareness of the rising rate of resistant bacteria around the world and the dangers they pose.

When I was in high school and college, I volunteered at a children’s cancer facility. Back then, I interacted with children who had a higher risk of infection. This experience led me to pursue a career in the medical field and, in particular, pediatrics healthcare. Ultimately, I settled on a specialty in pediatric infectious diseases.

During my career, I received the Helen’s Grant Fund (2017) from the Dartmouth-Hitchcock Medical Center. This award funded my research on the early onset neonatal sepsis systematic review.

My research has been published in the journal Diagnostic Microbiology and Infectious Disease. Lastly, I am fluent in English, French and Arabic. I’m learning Spanish and hope to become fluent soon.


Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review. Peck, GM; Staat, MA; Huang, FS; Khalil, N; Boyce, C; Kohlrieser, CM; Schlaudecker, EP. Pediatric Pulmonology. 2021; 56:2695-2699.

Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; et al. Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Combined Molecular and Phenotypic Antimicrobial Susceptibility Testing Is Beneficial in Detection of ESBL and AmpC Beta-Lactamase Producing Isolates of Enterobacteriaceae in Pediatric Patients with Bloodstream Infections. Powell, EA; Khalil, N; Deburger, B; Mortensen, JE. Microbial Drug Resistance. 2020; 26:825-830.

Neonatal early onset sepsis in Middle Eastern countries: a systematic review. Khalil, N; Blunt, HB; Li, Z; Hartman, T. Archives of Disease in Childhood. 2020; 105:639-647.

Neonatal bacteremia and oligoarthritis caused by Rhodococcus corynebacterioides/Rhodococcus kroppenstedtii. Khalil, N; Corker, L; Powell, EA; Mortensen, JE. Diagnostic Microbiology and Infectious Disease. 2019; 94:395-397.